FDA begins technology overhaul in preparation for tsunami of data and real-world evidence

COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

COTA, a leader in real-world data and analytics for oncology, is entering a collaboration with Sanofi to use RWD and artificial intelligence to increase the speed of oncology trials, including for multiple myeloma.

April 19, 2024

Clinical Roundup

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Non-classical mutations are present in 20-30% of all patients with epidermal growth factor receptor-mutated non-small cell lung cancer, according to an analysis of real-world evidence presented by Black Diamond Therapeutics, Inc. at the American Association of Cancer Research annual meeting.

April 12, 2024

Vol.50 No.15

In Brief

Michael Egger, Christopher Manz, Serena Phillips receive 2023 Real-World Data Impact Award from ACS, Flatiron

Michael EggerChristopher ManzSerena PhillipsMichael Egger, Christopher Manz, and Serena Phillips received the 2023 Real-World Data Impact Award from the American Cancer Society and Flatiron Health.

March 08, 2024

Vol.50 No.10

Conversation with The Cancer Letter

Ellen Sigal, Roy Herbst: Friends and FDA to focus on real-world evidence, AI, and streamlined trials in 2024

As artificial intelligence becomes an indispensable tool in cancer research, drug sponsors and researchers should focus on building and utilizing rich real-world evidence databases that can be used to complement clinical trials.

February 09, 2024

Vol.50 No.06

By Paul Goldberg and Matthew Bin Han Ong

Clinical Roundup

JNCCN study: Real world data shows impact of immunotherapy in populations underrepresented in clinical trials

Patients treated with first-line immunotherapy for advanced non-small cell lung cancer showed similar results in terms of survival, progression-free survival, and treatment duration, regardless of race or ethnicity, even with differences in income and insurance, a study published in the Journal of the National Comprehensive Cancer Network showed.

December 15, 2023

Vol.49 No.46

Guest Editorial

Patients are the key to disruptive innovation in cancer. Why aren’t they at the table?

Today’s traditional research model relies on incremental innovation that builds upon the shoulders of other researchers’ work, making small but steady strides. Occasionally, leaps are made by researchers who develop new classes of therapy such as stem cell transplant or CAR-T immunotherapy. But cancer patients may not have the luxury to wait 20 years for the traditional scientific process to evolve for their cancer. They can’t wait for a cure.

November 10, 2023

Vol.49 No.42

By Jenny Ahlstrom

FDA begins technology overhaul in preparation for tsunami of data and real-world evidence

YOU MAY BE INTERESTED IN

COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Michael Egger, Christopher Manz, Serena Phillips receive 2023 Real-World Data Impact Award from ACS, Flatiron

Ellen Sigal, Roy Herbst: Friends and FDA to focus on real-world evidence, AI, and streamlined trials in 2024

JNCCN study: Real world data shows impact of immunotherapy in populations underrepresented in clinical trials

Patients are the key to disruptive innovation in cancer. Why aren’t they at the table?

Renew today!

Subscriber content

Login